Navigation Links
Evalve(R) Completes $60 Million Series D Financing
Date:11/27/2007

Financing Provides Capital to Complete EVEREST Pivotal Study and Begin

European Commercialization

Investigators Continue to Build on Initial Data Showing Durability, Efficacy & Safety of Evalve's MitraClip(R) Device for Percutaneous Repair

of Mitral Valve Regurgitation

MENLO PARK, Calif., Nov. 27 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that it had successfully completed a $60 million Series D financing. BBT Fund LP led the round and was joined by current Evalve investors including, Delphi Ventures, New Enterprise Associates, Split Rock Partners and Abbott Laboratories.

This financing will enable Evalve to begin preparations for commercialization of the MitraClip(R) device in Europe and continue to move toward U.S. approval of the product by completing enrollment in its EVEREST pivotal study. The MitraClip device is intended to treat mitral regurgitation (MR) by percutaneously repairing the mitral valve allowing patients to avoid the risks, trauma and costs associated with current open, arrested heart surgical treatment.

"The strong interest from both new and existing investors indicates a high level of confidence in our clinical results to date, as well as enthusiasm for our potential to improve the continuum of care for patients suffering from structural heart disease and the expanding market this represents," said Ferolyn Powell, President and Chief Executive Officer of Evalve. "We are pleased that this financing will allow Evalve to progress toward commercialization of our MitraClip device for percutaneous mitral repair."

Evalve also announced today changes to its board of directors. Ryan Perras, Principal at Apothecary Capital, will join the board while Dr. Thomas Fogarty will step down from his role as a director. Dr. Fogarty will continue his involvement with the company, joining as an investor in this round of funding through his new fund, Emergent Medical Ventures.

"We welcome Ryan to the board where his expertise and experience will be an important resource for Evalve as we move forward toward commercialization," said Ms. Powell. "At the same time, we are pleased that Dr. Fogarty will continue to be involved with the company. His contributions have been a strong factor in our success throughout our history and in the development of the MitraClip device."

EVEREST Study Continues Enrollment

The EVEREST II study continues at more than 35 centers in North America with more than 300 patients enrolled and more than 300 MitraClip devices implanted to date. Investigators are currently enrolling patients in both arms of the EVEREST II study -- a randomized, controlled arm and a high risk registry arm -- with the goal of completing enrollment by the end of 2008.
Enrollment in the study is open to a range of patients:

-- Patients with either degenerative or functional MR.

-- Patients who are good surgical candidates and are open to the option

of a less invasive approach.

-- High risk patients who are not good candidates for surgery will be

enrolled in the EVEREST High Risk Registry until enrollment is

complete in this arm by the end of 2007.

The EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) randomized study is evaluating the safety and efficacy of the MitraClip device compared to surgical mitral valve repair or replacement. This prospective, randomized, multi-center study will enroll 279 patients at up to 42 sites in the United States and Canada. Patients are randomized 2:1 to receive the MitraClip device. Patients who are interested in participation in the study can call 1-877-MY-MR-FIX (1-877-696-7349). More information about the EVEREST II trial is available at http://www.mitralregurgitation.org.

About Mitral Regurgitation

Mitral regurgitation (MR), the most common type of heart valve insufficiency occurs when the heart's mitral valve does not close properly. Both the American Heart Association and the American College of Cardiology recommend open-heart surgery to repair or replace the mitral valve for patients who suffer from moderate-to-severe (Grade 3+) and severe (Grade 4+) MR; open heart surgery is not recommended for patients with 1-2+ MR. An estimated four million people in the United States have significant (greater than 2+) MR, with an annual incidence of 250,000 newly diagnosed patients.

About Evalve, Inc.

Evalve, Inc. (Menlo Park, Calif.) was incorporated in 1999 to design, develop, manufacture, and market innovate devices to enable percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. The company's present development and clinical efforts are focused on mitral valve repair. For more information about Evalve, Inc., and for an animated explanation of the Percutaneous Mitral Repair procedure using the MitraClip device, visit http://www.evalveinc.com. Evalve is the first portfolio company from the medical device company incubator, The Foundry (http://www.thefoundry.com).

MitraClip and Evalve are registered trademarks of Evalve, Inc.


'/>"/>
SOURCE Evalve, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... LARKR™ , an innovative new smartphone app ... across the country to join its online treatment platform. , Launching in just ... a substantially greater number of people in need nationwide, and to supplement their traditional ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing teeth ... with or without a referral. Dr. Cotey is a trusted dentist who has placed ... replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged to find ...
(Date:6/25/2017)... , ... June 25, 2017 , ... Republicans in the ... and replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the ... will need to be reconciled in committee, or the House will have to take ...
(Date:6/25/2017)... ... ... heatwave currently bearing down on Northern California pushing temperatures to the maximum, many people are ... with laser hair removal. , The process of summer waxing and constantly shaving unwanted ... want to do is get out, dive in and cool off. There is a way ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... PA at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... experience, exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... CAESAREA, Israel , May 30, 2017 DarioHealth Corp. ... and big data solutions, today announced that it will be presenting ... 2017, at 8:00 AM PT. Erez Raphael , CEO, of ... The conference will be held on June 6th & 7th, ... 180 companies in the small / micro-cap space. ...
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology: